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Nuclear hormone receptors (NRs) form a family of transcription factors that
mediate cellular responses initiated by hormone binding. It is generally
recognized that the structure and dynamics of the C-terminal helix 12 (H12) of
NRs' ligand binding domain (LBD) are fundamental to the recognition of
coactivators and corepressors that modulate receptor function. Here we study
the role of three mutations in the I280 residue of H12 of thyroid hormone
receptors using site-directed mutagenesis, functional assays, and molecular
dynamics simulations. Although residues at position 280 do not interact with
coactivators or with the ligand, we show that its mutations can selectively
block coactivator and corepressor binding, and affect hormone binding affinity
differently. Molecular dynamics simulations suggest that ligand affinity is
reduced by indirectly displacing the ligand in the binding pocket, facilitating
water penetration and ligand destabilization. Mutations I280R and I280K link
H12 to the LBD by forming salt bridges with E457 in H12, stabilizing H12 in a
conformation that blocks both corepressor and coactivator recruitment. The
I280M mutation, in turn, blocks corepressor binding, but appears to enhance
coactivator affinity, suggesting stabilization of H12 in agonist conformation.
© 2011 Elsevier Ltd. All rights reserved.
Introduction
Thyroid hormone receptors (TRs) are transcription
factors modulated by thyroid hormone binding.1–3
They belong to the nuclear hormone receptor (NR)
superfamily, one of the major targets of pharmaceu-
ticals comprising receptors for estrogens and its
analogs, corticosteroids, and retinoic acid and de-
rivatives, to mention a few. NRs contain three
domains: a variable N-terminal domain with un-
known structure, a DNA binding domain that
recognizes DNA response elements, and a ligand
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binding domain (LBD) that selectively recognizes
hormones and contains interfaces for dimerization
and cofactor recruitment.4–10
The structure and dynamics of the LBD are
essential for transcription regulation. It is currently
accepted that in the absence of ligand, the C-terminal
helix [helix 12 (H12)] of the LBD is positioned
such that it exposes an interface for corepressor
binding. In positively regulated genes, the NR
inhibits gene transcription while bound to the
corepressor. Ligand binding perturbs the dynamic
equilibrium of H12, which adopts a novel
preferential orientation that favors coactivator—
instead of corepressor—recruitment. Dissociation
of corepressor and binding of coactivator initiate
transcription.8–10 Thus, H12 conformation and
dynamics are key factors that modulate ligand-
dependent transcription regulation.
The dynamics of H12 was initially believed to
involve its detachment from the body of the LBD, as
exemplified by apo retinoid X receptor (RXR) and
holo retinoic acid receptor (RAR) crystallographic
structures.11,12 The recruitment of corepressors and
coactivators with specific H12 conformations sug-
gests that the movements of H12 are more subtle, as
shown in Fig. 1, and are mostly determined by
preferential orientations H12 assumes while docked
to the surface of the LBD. Ligand entry and exit may
occur through subtle movements of H12 or other
structural elements. Other crystal structures of apo-
LBDs,13–17 the constitutive activity of receptors,18–21
molecular dynamics (MD) computer simulation
studies,22–27 and hydrogen–deuterium exchange
experiments28–34 support the view of a dynamic but
compact LBD in which H12 can assume both
corepressor-favorable and coactivator-favorable con-
formations in the presence or in the absence of ligand,
but with different populations in each case.
In TRs, corepressor and coactivator interfaces
overlap and are formed by residues V284, K288,
I302, and K306 from helices 3, 5, and 6 (residue
numbering according to TRβ isoform). The core-
pressor binding surface is further complemented by
residues T277, I280, T281, V283, and C309, which
also belong to helices 3, 5, and 6 but are spatially
closer to H12 in holo-TR, whereas the coactivators
require residues L454 and E457 from H12 to interact
with TR.35–37
Fig. 1. Structure models of TRβ based on X-ray diffraction data (holo model, gray; PDB ID: 3GWS) and hydrogen–
deuterium exchange (apo model; black) suggesting conformational rearrangements through which H12 undergoes ligand
binding. The displacement of H12 from the holo conformation results in the exposure of the corepressor binding surface.
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H12 is docked over residues I280, V283, and C309
in holo-TR structures, so that corepressor binding
requires a conformational shift of H12 from this
position. The role of these three residues (I280, V283,
and C309) in coactivator and corepressor binding is
essential for the comprehension of H12 conforma-
tional equilibrium and dynamics. As coactivator—
but not corepressor—binding is dependent on direct
interactions with H12, deletion of H12 blocks
coactivator interactions but increases corepressor
association by exposing its interaction surface.37
Some mutants in this region are also linked to
resistance-to-thyroid-hormone syndrome,38–40
which is usually associated with reduced transcrip-
tional activity and reduced hormone affinity for the
receptor.41
Here, we report an experimental and computa-
tional study of the effects of mutations I280M, I280R,
and I280K on the association of coactivators and
corepressors, heterodimerization, and ligand affini-
ty. We show that different mutations at position 280
affect each of these functional characteristics of the
receptors differently, and MD simulations provide
the structural basis for such differential effects.
Results and Discussion
Mutants impair transcriptional activity
Reporter gene assays were used to probe the
transcriptional activities of native and mutant
I280M, I280R, I280K, F451X, and I280K/F451X.
Only mutant I280M preserved significant levels of
transcriptional activity relative to wild-type TRβ, as
shown in Fig. 2a–c. The relative transcriptional
activity is response-element-dependent for each
mutant: I280M preserved about 82% of native
activity in DR4, 42% of native activity in F2, and
63% of native activity in TREpal. Activation pro-
moted by mutants I280R, I280K, F451X, and I280R/
F451X was significantly impaired and similar to
basal transcription activity.
Mutants modulate affinity for coactivators
and corepressors
As transcriptional activity is dependent on core-
pressor dissociation and coactivator binding, we
Fig. 2. Transcription activation upon different DNA response elements and coregulator recruitment promoted by
native andmutant TRβ. (a) DR-4. U937 cells were cotransfected with 4 μg of DR-4 LUC and 0.5 μg of the expression vector
of TRβ1 wild type and mutants and treated with vehicle or 100 nM T3. Data represent fold T3 inductions obtained at each
amount of TR expression vector and represent the average of the experiments. (b) As above, with F2-LUC. (c) As above,
with Pal-LUC. (d) Pull-down experiments examining the binding of 35S-labeled TRβ1 wild type or mutants to GST-SMRT,
GST-SRC, and GST-GRIP protein fragment in the presence or in the absence of 10−6 M T3.
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probe the affinity of native TRβ and mutant
constructs for the corepressor peptide SMRT and
for the coactivator peptides SRC and GRIP. As
shown in Fig. 2d, SMRT corepressor dissociation
from native TRβ–LBD, as expected, was fully
determined by ligand (T3) binding. At the same
time, ligand binding induces coactivator attachment
to the LBD. Mutants have different effects on these
trends: the I280R mutant preserves decreased SMRT
affinity, which is mostly ligand-insensitive (Fig. 2d).
The association of coactivators is also significantly
perturbed, and residual association with SRC and no
associationwithGRIP resulted. The I280Kmutant, in
turn, almost completely hampers coactivator and
corepressor binding under all conditions. The I280M
mutant is mostly unable to recruit the SMRT
corepressor, but it conserves coactivator binding
with ligand and, furthermore, has some coactivator
affinity even in the absence of ligand. Finally, the
mutation I280R also hampers corepressor binding in
the F451X construct. The F451X construct is known
to strongly bind corepressors by completely expos-
ing the corepressor binding surface.37,42
The effect of mutations on ligand binding affinity
Ligand binding is fundamental to coactivator
recruitment and, thus, to transcriptional activity.
Trypsin digestion assays were used to probe the
protection promoted by the ligand on the LBD and
thus to qualitatively evaluate ligand affinity. LBD
protection against trypsin digestion is characterized
by the appearance of a 28-kDa fraction on glutathi-
one S-transferase (GST) assays, as shown in Fig. 3a.
The same fragment is observed for micromolar T3
concentrations for the I280M mutation, but it is not
observed for I280R or I280K. Thus, the latter two
mutants appear to fully inhibit ligand binding, even
though residues in position 280 do not interact
directly with the ligand. The complete removal of
H12 (F451X construct) also reduces ligand affinity to
undetectable levels, as previously noted.37,42 T3
affinities for TRβ and for the I280M mutant were
then compared (Fig. 3b and c): Kd=0.13 nM for wild-
type TRβ and Kd=0.45 nM for I280M mutant.
In summary,GST experiments show that the affinity
of the SMRT corepressor peptide interacts with native
or mutant LBDs with the following preference: native
TRβNTRβ-I280M~TRβ-I280RNTRβ-I280K. Con-
cerning interactions with the coactivator peptides
SRC-1 and GRIP1, the affinity of the I280M mutant
is not affected relative to the native state such that
the affinities vary as follows: native TRβ=TRβ-
I280MNTRβ-I280RNTRβ-I280K. Therefore, different
mutations at position 280 affect coactivator and
corepressor recruitment differently. Additionally, all
mutants impair hormone binding. The affinities of
T3 for I280R and I280K are reduced such that
ligand binding could not be detected, and the
I280M displayed 29% of native TRβ affinity. At the
same time, the native and mutant LBDs hetero-
dimerize with RXR with similar affinities, support-
ing the correct overall fold of the mutant LBDs
(data not shown).
Fig. 3. T3 binding affinity for
native and mutant TRβ1. (a) [35S]
TRβ1 ormutantswere preincubated
with T3 (10
−8, 10−7, and 10−6 M) or
vehicle (ethanol) for 20 min at room
temperature before addition of tryp-
sin (concentration of 10 mg/ml).
Proteolytic digestions were carried
out at 37 °C for 10 min, and then
samples were denatured and elec-
trophoresed on SDS polyacryl-
amide gel. The 28-kDa band
represents the T3-protected TRβ1
fragment. Binding of [125I]T3 to
full-length TRβ1wt (b) and I280M
(c) mutant produced by in vitro
translation.
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Structural basis for perturbations on cofactor
recruitment
The mutations at position 280 affect both binding
affinity and the direct interactions of H12 with the
LBD core; thus, there are multiple possible in-
terpretations for their effect on coactivator recruit-
ment. The deletion of H12 hampers coactivator
binding, so that mutations that fully destabilize this
helix should have the same effect. Also, it is clear
that I280R and I280K mutations disrupt direct
corepressor–LBD interactions, which should be
hydrophobic at position 280. The observed lack of
SMRT affinity for F451X/I280K supports this
interpretation. However, the destabilization of H12
is not the only possible explanation for mutant
effects, as MD simulations suggest. Indeed, trapping
H12 in a conformation that blocks both coactivator
and corepressor surfaces would result in similar
experimental observations.
MD simulations support the experimental obser-
vation that the overall fold of the LBD is not altered
upon mutations of residue I280, as shown in Figs. 4
and 5a. There is a small increase in RMSD from the
native structure, never surpassing 2.0 Å for any
mutant. The radii of gyration and the α-helical
contents of the simulated mutants remain essentially
identical with those of the native LBD. There is,
however, a small but systematic loss of native
contacts for all three mutants relative to the native
TRβ structure: mutants lose about 5–8% native
contacts during the course of the simulations.
The structural basis of the effect of I280 mutations
on cofactor recruitment can be deduced from the
analysis of H12 structure and dynamics. As shown
in Fig. 5b, there is a significant displacement of H12
in mutants I280R and I280K, but not I280M, relative
Fig. 4. Global structural features of the LBD through
simulations: RMSDs of Cα atoms (RMSD), radius of
gyration (Rg), percentage of native contacts (% Ncont),
and percentage of secondary structure (% Nsec).
Fig. 5. Average structures from MD simulations. (a) The global folds of native and mutants are similar, but with
significant perturbations of the H12 position in I280K and I280R mutants. (b) Detail of the movements of H12 and the
interaction of Glu457, from H12, with mutant residues Lys and Arg in position 280. (c) Coactivator binding to the LBD is
dependent on the interaction of Glu457 with the main chain of the coactivator peptide, as observed in crystallographic
models (PDB ID: 1BSX).43 Mutants I280K and I280R compete with these interactions, destabilizing coactivator association.
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to its position in native holo-TRβ. The position of
H12 in this holo model forms the coactivator
binding surface such that perturbations of this
position should impair coactivator recruitment.
Indeed, as observed experimentally, coactivator
recruitment is impaired by mutations I280R and
I280K, but not I280M, consistent with the displace-
ments of H12 in each case. The perturbation of H12
position in I280R and I280K occurs, however, not by
the introduction of steric clashes that destabilize
H12. On the contrary, Arg and Lys residues at
position 280 form a stable salt bridge with H12
residue Glu457 that is located on the TR–LBD
surface and away from the ligand binding pocket,
as shown in Fig. 5b. This salt bridge introduces a
restraint on the position of H12 relative to the LBD,
displacing it from its functional position. The
displacement of H12 is not the only factor affecting
coactivator affinity for the LBD of I280R and I280K:
coactivator binding, as observed in crystallographic
models (Fig. 5c), depends on the direct interactions
of Glu457 with the coactivator peptide backbone.43
Therefore, substituting I280 with basic residues,
more than simply perturbing H12 position, causes
them to compete for the negatively charged Glu457,
reducing one of the main interactions of the
coactivator peptide with the LBD. TR coactivator
recruitment measurements and functional assays
with the E457A mutant already confirm the impor-
tance of this residue.40 Substitution I280M, in turn,
does not perturb the H12 position because isoleucine
and methionine residues share similar volumes and
are both hydrophobic. The competition of the Met
residue for Glu457 does not occur, thus preserving
coactivator binding affinity for the LBD.
The interpretation of corepressor binding affinity
differences has to be indirect, as there are no crystal
structures for corepressor-bound TRs or apo-TRs
(only a preliminary low-resolution model exists
based on results from hydrogen–deuterium ex-
change experiments and high-temperature MD
simulations).34 It is known, however, that corepres-
sor binding requires the displacement of H12 from
the holo-LBD position and docking in an alternative
conformation that exposes, for instance, residue I280.
With this in mind, we propose that the strong
interactions that R280 and K280 form with Glu457
impair corepressor recruitment by not allowing H12
to assume the position that establishes the corepres-
sor binding surface. Additionally, the direct hydro-
phobic contact between corepressor and I280 is lost
by apolar-to-polar substitution. This direct mecha-
nism is consistent with the reduced corepressor
affinity of the F451X/I280K construct. At the same
time, the I280M mutation also impairs corepressor
recruitment experimentally, and no alteration inH12
position was observed. It is possible that a Met
residue in position 280 promotes some degree of
stabilization of the H12 native holo conformation,
thus also hampering the formation of the corepressor
binding surface. This is consistent with the increase
in the coactivator binding affinity of I280M relative
to wild-type TRβ, particularly in the absence of
ligand. As the interaction energies involved in
hydrophobic interactions are more subtle and as no
alterations in H12 position or dynamics were
observed, further investigations are required to
confirm this hypothesis.
H12 stabilization in a closed conformation has also
been suggested for other NRs. For example, differ-
ent mutations in residue Y537, located in H12 of
estrogen receptor α, modulate transcriptional activ-
ity, coregulator recruitment, and ligand association/
dissociation rates. These features are associated with
H12 stabilization in the agonist conformation in the
apo estrogen receptor α.44–46 The same interpreta-
tion was proposed for isoforms β and γ of RAR. A
few differences in residues in helix 3 and in the
C-terminal extension of H12 relative to the RARα
isoform are associated with a reduced interaction
with corepressors and the observation of constitutive
transcriptional activity.47,48 In addition, twomutants
in H12 (L468A and E471A) of the peroxisome
proliferator activator receptor have been shown to
elicit similar behaviors.49
Molecular interpretation of mutation effects on
ligand affinity
Experimentally, all three I280M, I280R, and I280K
mutations reduce T3 binding affinity. T3 affinity for
I280M mutant is about 29% of the affinity for native
LBD, whereas no detectable ligand binding could be
observed for I280R and I280K. Since the residues at
position 280 do not interact with the ligand, the
effect of the mutations on ligand binding affinity
must be indirect. Figure 6 displays structural and
energetic features of T3 in the binding pocket of
native and mutant structures. The position of the
ligand relative to H12 (as measured by the distance
between ligand and H12 residues) is not perturbed,
except for the I280K mutation (Fig. 6a). Even in this
case, the drift is gradually restored to the initial
relative orientation between T3 and H12. However,
movements of H12 triggered by the mutations
displace the ligand and affect its contact with the
arginine residues of the β-hairpin, located on the
opposite side of the binding pocket. The β-hairpin–
T3 distance indicates that the ligand shifts by about
2 Å from the arginines for all mutants relative to the
native structure.
This conformational adaptation affects both
ligand–protein interactions and the hydration
level of the ligand in the binding pocket. The
LBD–T3 interactions in the cases of I280R and
I280K, and for the I280M mutant to a lesser extent,
turn out weaker than that of the native structure, as
shown in Fig. 6b. Up to seven water molecules
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penetrate the binding pocket for the I280R and
I280K mutants and increase ligand–solvent interac-
tions (Fig. 6c). Further inspection of ligand hydra-
tion inside the binding pocket reveals that up to
three of these molecules are in contact with the
hydrophobic body of T3. No extra water molecule,
relative to the native structure, occupies the binding
pocket for I280M. However, whereas ligand–water
interactions in the native LBD occur solely via the
ligand's hydrophilic head, the increased flexibility
of the I280M mutant binding pocket allows water
to interact with the aromatic rings of T3 in I280M.
The displacement of H12 in mutants induces some
repositioning of the ligand in the binding pocket,
and T3–β-hairpin hydrophilic contacts are replaced
by interactions with water molecules. The position
of T3 relative to H12 is preserved because hydro-
phobic contacts are largely maintained within the
binding pocket. The ligand becomes loosely at-
tached to the binding pocket, and water molecules
are allowed to interact with its hydrophobic
residues. The number of water molecules that can
penetrate the binding pocket and interact with the
hydrophobic parts of T3 is larger for I280R and
I280K mutations than for I280M because the
perturbations that the former mutations promote
on the H12 structure are larger. The simulations
suggest that the observed lower ligand binding
affinity of the mutants relative to the native
structure stems from a combination of these effects,
particularly from the partial destabilization of
ligand–LBD hydrophobic contacts due to water
penetration into the hydrophobic core of the binding
pocket. Thus, structural perturbations of H12 can
affect ligand affinity indirectly by displacing the
ligand in the binding pocket even if direct ligand–
H12 interactions are preserved. Interactions with
water molecules in the binding pocket seem to be
important to the affinity, selectivity, dissociation,
and association of ligands in TRs.23,25,50,51
Mutants in the same region in other NRs may
have similar effects on ligand binding affinity.
However, multiple sequence alignment (MSA) of
the TR-like subfamily shows distinct sequence
patterns in the I280 region (343 MSA position),52
which would indicate differentiation of behaviors
between receptors. For example, at the same
sequence position, V293A mutation in peroxisome
proliferator activator receptor γ does not impair
receptor functions,53 whereas double mutations in
RARs (one of them at the same MSA position) can
change the ligand affinity and selectivity for
different isoforms.54
Conclusions
The conformation and mobility of NRs' H12 are
key structural factors affecting NR transcriptional
activity. H12 is mobile and assumes different
preferential conformations in the presence and in
the absence of ligand. However, the few structural
models of apo-LBDs and limited direct experimental
information on H12 and LBD dynamics result in the
incomplete comprehension of relationships between
NR dynamics and function. Here, we address the
Fig. 6. Displacements of H12 indirectly result in perturbations of the ligand binding pocket, allowing water
permeation. (a) Representative snapshots from the simulations showing the movements of H12 water insertion. (b)
Distances of T3 to H12 (T3–H12) and the β-hairpin (T3–β-hp), and interaction energies with the LBD (LBD–T3) and water
molecules (Sol–T3). (c) Number of water molecules solvating T3 (Nsolv) and, in particular, its hydrophobic body (Nhydrop),
which may destabilize ligand binding.
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effects of the I280mutants of the LBD of TR to further
understand the relationships between perturbations
of H12 position and TR function. We have shown
that I280 mutations to positively charged residues
impair ligand, corepressor, and coactivator binding.
This can be explained by two mechanisms: (1) the
complete destabilization of H12 position relative to
LBD, with total exposure of residues at position 280,
consistent with a similar loss of functionality of the
complete deletion of H12; and (2) the stabilization of
H12 in alternative, but incorrectly docked, confor-
mations in I280K and I280R, which results from the
formation of a salt bridge between the residue side
chain at position 280 and Glu457. The incorrect
docking of H12 blocks the corepressor binding
surface and also cannot establish the coactivator
binding surface. Ligand binding is affected by these
mutations indirectly by facilitating water penetra-
tion in the active site that destabilizes hydrophobic
ligand binding pocket interactions.
Materials and Methods
Plasmid vectors
The construction of plasmids used for the synthesis of
TRβ1 (pCMX-hTRβ1) had been previously described.35,55,56
Vectors encoding TRβ1 with an exchange of isoleucine 280
with lysine ormethionine (pCMX-I280K and pCMX-I280M)
were donated by Professor Brian West and have been
alreadydescribed.37 The vectorswithmutation of isoleucine
280 to arginine (pCMX-I280R) and with deletion of the last
10 amino acids of TRβ1 (pCMX-F451X) were generated by
site-directed mutagenesis (QuickChange Site-Directed Mu-
tagenesis; Stratagene) employing primers containing the
required nucleotide sequence. The double mutant I280R/
F451X was constructed by adding mutation I280R to
pCMX-F451X.
The plasmids for the expression of proteins fused with
GSTwere pGEx (Pharmacia-Upjohn), pGEX-SRC-1 (residues
381–882),35 pGEX-GRIP-1 (residues 563–767), pGEX-SMRT
(residues 987–1491),56,57 and pGEX-RXR (full),35 which
encode proteins GST, GST-SRC-1, GST-GRIP-1, GST-SMRT,
and GST-RXR, respectively. The reporter plasmids contain-
ing the elements of positive responses DR4/F2/TREpal-TK-
LUC and negatively regulated promoter Δ Coll T3-LUC
58,59
were donated by Dr. John D. Baxter.
Expression and purification of recombinant proteins
in Escherichia coli
Proteins fused with GST were expressed in E. coli and
purified according to the protocol described below: 50 μl of
the E. coli bacterium strain BL21 was transformed with
1–2 ng of plasmid, pGEX, pGEX-SRC1 (residues 381–882),
pGEX-GRIP1 (residues 563–767), or pGEX-SMRT (residues
987–1491), which expresses the respective protein frag-
ments fused to GST. The isolated colony was inoculated in
5ml of 2× LBmedium (preinoculum) and grown for 6–10 h
at 22 °C. Subsequently, the preinoculumwas split into two
bottles containing 500ml of 2× LBmediumwith ampicillin.
Bacteria were induced with 1 mM IPTG at an OD600 of 0.8
for 16 h at 22 °C so that the fusion protein was expressed.
After this period, the culture was centrifuged, and the cell
pellets were combined and suspended in 20 ml of 1× TST
[50 mMTris (pH 7.5), 150 mMNaCl, and 0.05% Tween 20].
Five hundred microliters of lysozyme (10 mg/ml) was
added and incubated on ice for 15 min. Cells were then
sonicated (four pulses of 20 s at level 5.5 with a 5-min
interval between each pulse). Soon after, the cell lysate was
separated by centrifugation at 12,000 rpm for 30 min.
Concurrently, 665 μl of glutathione beads was prepared
according to the manufacturer's instructions. Briefly, the
beads were washed with 5 vol of 1× TST and separated by
rapid centrifugation (5000 rpm for 2min). Then, in order to
allow the interaction of beads with the GST, we resus-
pended the beads in 500 μl of 1×TST and added them to the
culture supernatant. This incubation was maintained at
4 °C for 2 h. The beads were collected by centrifugation at
5000 rpm for 5min and thenwashed three timeswith 20ml
of 1× TST. After the beads had been washed, they were
resuspended in 600 μl of 1× TST containing 1 mM DTT,
0.5 mM PMSF, 1:1000 protease inhibitor cocktail (Sigma),
and 1 ml of glycerol. The beads containing the fusion
proteins were stored at −20 °C until their use in GST
experiments on protein–protein interaction in solution.
GST constructs bound to the resin were quantified with
Coomassie Plus Protein Assay Reagent (Pierce) according
to the manufacturer's instructions and submitted to
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) to assess purity (90–95%).
GST assay (GST pull-down assay)
For these experiments, 35S-labeled TRs were produced
in vitro with pCMX-TRβ1wt or pCMX mutant vectors
using the TNT-Coupled Reticulocyte Lysate System
(Promega, Madison, WI) containing a methionine-free
amino acid mixture. DNA plasmid (1–2 μg), together with
35S-labeled methionine, was added to the TNT Quick
Master Mix and incubated in 50 μl for 90 min at 30 °C. To
confirm the efficiency of the translation of 35S-labeled
proteins, we submitted the final mixture to SDS-PAGE,
dried it, and visualized it by autoradiography. The
binding experiments were performed by mixing glutathi-
one-linked Sepharose beads containing 10 μg of GST-
SMRT (residues 987–1491), GST-SRC-1 (residues 381–882),
and GST-GRIP-1 (residues 563–767) fusion proteins with
3 μl of 35S-labeled wild-type or mutant hTRβ1 in 150 μl of
binding buffer (20 mM Hepes, 150 mM KCl, 25 mM
MgCl2, 10% glycerol, 1 mM dithiothreitol, 0.2 mM
phenylmethylsulfonyl fluoride, and protease inhibitors)
containing 2 μg/ml bovine serum albumin for 100 min at
4 °C. After the incubation, the beads were washed three
times with 1 ml of binding buffer, and the bound proteins
were separated using 10% polyacrylamide gels containing
SDS (SDS-PAGE) and visualized by autoradiography.60
Cell culture, transfection, and luciferase enzyme
activity assays
The procedures for cell culture, transfection, and
luciferase enzyme activity assays were performed
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according to methods described previously.61Human
promonocyte (U937) was obtained from the Cell Culture
Facility at the University of California, San Francisco.
These cells were cultured in RPMI 1640 containing 10% of
fetal bovine serum with 2 mM glutamine, 50 μg/ml
penicillin, and 50 μg/ml streptomycin, and kept in an
incubator at 37 °C in 5% CO2. The electroporation method
was used for the transfection of cells maintained in
culture. U937 cells (9 million) were collected by centrifu-
gation and suspended in 0.5 ml of phosphate-buffered
saline containing 0.1% of dextrose. These cells were then
mixed with 4 μg of reporter plasmid and 0.5 μg of TRβ1
expression vector and then transferred to a cuvette. After
storage at room temperature for 5 min, they were
electroporated using a pulse generator (Bio-Rad) at 0.3 V
and 960 μF. After electroporation, the cells were trans-
ferred to fresh media and then plated on 12-well multi-
plates containing RPMI 1640 with 10% of fetal bovine
serum and incubated for 24 h at 37 °C with ethanol
(vehicle) or T3 (10
−7 M). After 24 h, the cells were collected
by centrifugation, lysed by the addition of 150 μl of 1×
lysis buffer (Luciferase Assay System; Promega), and
assayed for luciferase activity in a luminometer (Turner).
Transfection data are expressed as the mean±standard
error of the mean of a minimum of triplicate samples,
repeated three to five times. The empty vector pCMX was
used as control for transfections without TRβ1.
Site-directed mutagenesis
Mutants I280R, F451X, and I280R/F451X were generat-
ed by the PCR site-directed mutagenesis technique
(QuickChange Site-Directed Mutagenesis; Stratagene),
which employs synthetic oligonucleotides as primers
containing the sequence of nucleotides mutated (substi-
tution at an encoder codon of correct amino acid by an
encoder of arginine or a stop codon, in the case of F451X).
pCMX-hTRβ1 was amplified using high-fidelity plaque-
forming unit DNA polymerase enzyme to generate
mutant plasmids. The mutated sequence was verified by
DNA sequencing (Sequenase; Stratagene).
Trypsin protection assays
Three micrograms of wild-type TRβ1 or mutants
synthesized in vitro with Met-35S was preincubated with
T3 (10
−8, 10−7, and 10−6 M) or vehicle (ethanol) for 20 min
at room temperature in a final volume of 10 μl of 1× TST.
Then trypsin was added (at a concentration of 10 mg/ml
in the reaction) for 10 min at 37 °C. The products of the
reactions were boiled and analyzed by SDS-PAGE,
followed by autoradiography.20
T3 binding assay
TRs were expressed using a kit (TNT T7-Quick Coupled
Transcription/Translation System; Promega). T3 binding
affinities were determined using saturating binding assay.
Briefly, 15 fM of each synthesized protein in vitro was
incubated overnight at 4 °Cwith varying concentrations of
T3 labeled with
125I (PerkinElmer Life Sciences) in 100 μl of
E400 buffer [400 mM NaCl, 20 mM K3PO4 (pH 8), 0.5 mM
ethylenediaminetetraacetic acid, 1.0 mM MgCl2, and 10%
of glycerol], 1 mM monothioglycerol, and 50 μg of calf
thymus histones (Calbiochem). T3-
125I was isolated by
gravity through a 2-ml Sephadex G-25 column (Amer-
sham Biosciences) and quantified in a γ-counter (COBRA;
Packard Instruments). The binding curves were fitted by
nonlinear regression, and the binding dissociation con-
stants (Kd) were calculated using the one-site saturation
binding model and one-phase exponential decay, respec-
tively, present in the PRISM program, version 4.0
(GraphPad Software, Inc., San Diego, CA).
Statistical analysis
All results presented here represent the mean and
standard deviation of at least four independent experi-
ments. All statistical analyses and graphics were per-
formed using the PRISM program, version 4.0 (GraphPad
Software, Inc.). The statistical analysis test used in the
experiments was analysis of variance, followed by Tukey
test. Results were considered statistically different when
the p value was smaller than 0.05. The differences or
similarities are represented in the form of letters (a, b, c,
and d) over the bars. Different letters indicate significant
differences between the groups, and identical letters
indicate that there is no statistical difference.
MD simulations
The initial protein structure was the LBD of wild-type
TRβ1 bound to T3, obtained by our research group [Protein
Data Bank (PDB) ID: 3GWS].62 Missing Ω-loop (residues
253–262) was modeled based on the corresponding region
of wild-type TRα–LBD (PDB ID: 2H79).62 The complete
simulated systems—containing TRβ1–LBD, water, and
one counterion for each charged residue for electroneu-
trality—were built with Packmol.63,64 We use a cubic box
with 16,600 water molecules with side dimensions of 81 Å.
For the simulation ofmutant structures, the simulation box
of the wild-type structure was used, and the side chain of
residue 280 was substituted with the psfgen program.65,66
For I280K and I280R, a random water molecule was
replaced by a chloride ion to maintain electroneutrality.
Four systems were therefore built: wild-type TRβ1, I280M,
I280K, and I280R.
MD simulations were performed with NAMD65,66 by
applying periodic boundary conditions and CHARMM
parameters.67 The TIP3P model was used for water.68 T3
parameters had been reported previously.22 A time step of
2.0 fs was used, and all hydrogen-to-heavy-atom bonds
were kept rigid. A 14-Å cutoff with smooth switching
function starting at 12 Å was used for van der Waals
interactions, whereas electrostatic forces were treated via
the particle mesh Ewald method.69
Energy minimization and equilibration were performed
independently for each system, as follows: total energies
were minimized by 700 conjugate gradient (CG) steps
keeping all protein atoms fixed, except for the modeled
regions, which were always allowed to move. Fixing only
the Cα atoms, we performed another 500 CG steps.
Finally, 300 CG steps were carried out without any
restrictions. After minimization, 4-ns MD simulations
were performed under conditions of constant temperature
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and pressure (NpT ensemble) at 298 K and 1 bar, with a
Langevin damping coefficient of 5 ps−1 andwith Langevin
piston controlled using a period of 200 fs and a decay of
100 fs. Atomic coordinates and NAMD files for MD
simulations are available from the authors upon request.
The temporal variations of the structural properties of
the protein were computed with the objective of deter-
mining the relaxation and stability of TR–LBDs, in
particular of mutants constructed from the wild-type
structure. The chosen structural properties were as
follows: RMSDs of the Cα atoms, RMSD; radius of
gyration Rg; percentage of native contacts, % Ncont;
percentage of secondary structure, % Nsec (for more
details, see Martínez et al.70). The initial structure of the
simulations was used as reference in these calculations. It
was found that the mutants lead to small losses of
secondary structure and native contacts, and small
increases in RMSDs. All global structural properties
have converged within 2 ns. Thus, the first 2 ns of the
simulations was not used for the analysis. Analyses were
performed for the last 2 ns of the trajectory using VMD71
and our home-made programs†.
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